325 related articles for article (PubMed ID: 16696479)
1. Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapy.
Wang JZ; Mayr NA; Nag S; Montebello J; Gupta N; Samsami N; Kanellitsas C
Med Phys; 2006 Apr; 33(4):1025-32. PubMed ID: 16696479
[TBL] [Abstract][Full Text] [Related]
2. Potential impact of prostate edema on the dosimetry of permanent seed implants using the new 131Cs (model CS-1) seeds.
Chen Z; Deng J; Roberts K; Nath R
Med Phys; 2006 Apr; 33(4):968-75. PubMed ID: 16696473
[TBL] [Abstract][Full Text] [Related]
3. Prescription dose in permanent (131)Cs seed prostate implants.
Yue N; Heron DE; Komanduri K; Huq MS
Med Phys; 2005 Aug; 32(8):2496-502. PubMed ID: 16193779
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations.
Li XA; Wang JZ; Stewart RD; DiBiase SJ
Phys Med Biol; 2003 Sep; 48(17):2753-65. PubMed ID: 14516099
[TBL] [Abstract][Full Text] [Related]
5. Determination of the prescription dose for biradionuclide permanent prostate brachytherapy.
Nuttens VE; Lucas S
Med Phys; 2008 Dec; 35(12):5451-62. PubMed ID: 19175105
[TBL] [Abstract][Full Text] [Related]
6. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
[TBL] [Abstract][Full Text] [Related]
8. Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants--a bio-mathematical model.
Yue N; Chen Z; Nath R
Phys Med Biol; 2002 Apr; 47(7):1185-204. PubMed ID: 11996063
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
Chibani O; Williamson JF; Todor D
Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
[TBL] [Abstract][Full Text] [Related]
10. Relationship between isotope half-life and prostatic edema for optimal prostate dose coverage in permanent seed implants.
Villeneuve M; Leclerc G; Lessard E; Pouliot J; Beaulieu L
Med Phys; 2008 May; 35(5):1970-7. PubMed ID: 18561673
[TBL] [Abstract][Full Text] [Related]
11. Isotope choice and the effect of edema on prostate brachytherapy dosimetry.
Butler WM; Merrick GS; Dorsey AT; Lief JH
Med Phys; 2000 May; 27(5):1067-75. PubMed ID: 10841411
[TBL] [Abstract][Full Text] [Related]
12. The impact of edema on planning 125I and 103Pd prostate implants.
Yue N; Dicker AP; Nath R; Waterman FM
Med Phys; 1999 May; 26(5):763-7. PubMed ID: 10360539
[TBL] [Abstract][Full Text] [Related]
13. A radiobiological investigation on dose and dose rate for permanent implant brachytherapy of breast using 125I or 103Pd sources.
Baltas D; Lymperopoulou G; Löffler E; Mavroidis P
Med Phys; 2010 Jun; 37(6):2572-86. PubMed ID: 20632569
[TBL] [Abstract][Full Text] [Related]
14. The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer.
Lindsay PE; Moiseenko VV; Van Dyk J; Battista JJ
Phys Med Biol; 2003 Feb; 48(4):507-22. PubMed ID: 12630745
[TBL] [Abstract][Full Text] [Related]
15. Effect of edema associated with 131Cs prostate permanent seed implants on dosimetric quality indices.
Kehwar TS; Jones HA; Huq MS; Beriwal S; Benoit RM; Smith RP
Med Phys; 2009 Aug; 36(8):3536-42. PubMed ID: 19746787
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
[TBL] [Abstract][Full Text] [Related]
17. The low alpha/beta ratio for prostate cancer: what does the clinical outcome of HDR brachytherapy tell us?
Wang JZ; Li XA; Yu CX; DiBiase SJ
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1101-8. PubMed ID: 14575842
[TBL] [Abstract][Full Text] [Related]
18. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
Todor DA; Barani IJ; Lin PS; Anscher MS
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
[TBL] [Abstract][Full Text] [Related]
19. A gEUD-based inverse planning technique for HDR prostate brachytherapy: feasibility study.
Giantsoudi D; Baltas D; Karabis A; Mavroidis P; Zamboglou N; Tselis N; Shi C; Papanikolaou N
Med Phys; 2013 Apr; 40(4):041704. PubMed ID: 23556874
[TBL] [Abstract][Full Text] [Related]
20. A radiobiological model for the relative biological effectiveness of high-dose-rate 252Cf brachytherapy.
Rivard MJ; Melhus CS; Zinkin HD; Stapleford LJ; Evans KE; Wazer DE; Odlozilíková A
Radiat Res; 2005 Sep; 164(3):319-23. PubMed ID: 16137205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
